ClinicalTrials.govpublic full text
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
glioblastoma, anaplastic astrocytoma, antisense, cancer, transforming growth factor beta2 (tgf-beta2), targeted therapy, immunotherapy, brain tumor, central nervous system (cns), convection-enhanced delivery (ced) / microperfusion, locoregional application, interventional
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 848256
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.